Value of Retrospective Fusion of PET and MR Images in Detection of Hepatic Metastases: Comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-Enhanced MRI

被引:117
|
作者
Donati, Olivio F. [1 ]
Hany, Thomas F. [2 ]
Reiner, Caecilia S. [1 ]
von Schulthess, Gustav K. [2 ]
Marincek, Borut [1 ]
Seifert, Burkhardt [3 ]
Weishaupt, Dominik [1 ]
机构
[1] Univ Zurich Hosp, Inst Diagnost Radiol, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Div Nucl Med, CH-8091 Zurich, Switzerland
[3] Univ Zurich, Inst Social & Prevent Med, Biostat Unit, CH-8006 Zurich, Switzerland
关键词
hepatology; MRI; oncology; PET/MRI; PET/CT; liver metastases; multimodality imaging; positron emission tomography; POSITRON-EMISSION-TOMOGRAPHY; COLORECTAL LIVER METASTASES; FDG-PET/CT; COMPUTED-TOMOGRAPHY; SPIRAL CT; RESECTION; IMPACT; CANCER; LESIONS; DIAGNOSIS;
D O I
10.2967/jnumed.109.068510
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The purpose of this study was to compare the accuracy of lesion detection and diagnostic confidence between F-18-FDG PET/CT, gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI, and retrospectively fused PET and MRI (PET/MRI). Methods: Thirty-seven patients (mean age +/- SD, 60.2 +/- 12 y) with suspected liver metastases underwent PET/CT and Gd-EOB-DTPA-enhanced MRI within 0-30 d (mean, 11.9 +/- 9 d). PET and Gd-EOB-DTPA-enhanced MR image data were retrospectively fused. Images were reviewed independently by 2 readers who identified and characterized liver lesions using PET/CT, Gd-EOB-DTPA-enhanced MRI, and PET/MRI. Each liver lesion was graded on a 5-point confidence scale ranging from definitely benign (grade of 1) to definitely malignant (grade of 5). The accuracy of each technique was determined by receiver-operating-characteristic analysis. Histopathology served as the standard of reference for all patients with malignant lesions. Results: A total of 85 liver lesions (55 liver metastases [65%] and 30 benign lesions [35%]) were present in 29 (78%) of the 37 patients. Twenty-four (65%) of the 37 patients had liver metastases. The detection rate of liver lesions was significantly lower for PET/CT than for Gd-EOB-DTPA-enhanced MRI (64% and 85%; P = 0.002). Sensitivity in the detection and characterization of liver metastases for PET/CT, Gd-EOB-DTPA-enhanced MRI, PET/MRI in reader 1, and PET/MRI in reader 2 was 76%, 91%, 93%, and 93%, respectively; the respective specificity values were 90%, 100%, 87%, and 97%. The difference in sensitivity between PET/CT and PET/MRI was significant (P = 0.023). The level of confidence regarding liver lesions larger than 1 cm in diameter was significantly higher in PET/MRI than in PET/CT (P = 0.046). Accuracy values (area under the receiver-operating-characteristic curve) for PET/CT, Gd-EOB-DTPA-enhanced MRI, PET/MRI in reader 1, and PET/MRI in reader 2 were 0.85, 0.94, 0.92, and 0.96, respectively. Conclusion: The sensitivity of Gd-EOB-DTPA-enhanced MRI and PET/MRI in the detection of liver metastases is higher than that of PET/CT. Diagnostic confidence was significantly better with PET/MRI than with PET/CT regarding lesions larger than 1 cm in diameter. Compared with Gd-EOB-DTPA-enhanced MRI, PET/MRI resulted in a nonsignificant increase in sensitivity and diagnostic confidence.
引用
收藏
页码:692 / 699
页数:8
相关论文
共 50 条
  • [41] Preliminary Study of Heterogenous Integrated 18F-FDG PET/MRI for Evaluation of PCNSL: Comparison to 18F-FDG PET/CT
    Zhou, Wenlan
    Feng, Jie
    Ren, Yunyan
    Wang, Quanshi
    Wu, Hubing
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [42] Prognostic value of pretherapeutic 18F-FDG PET/CT (PET) and MRI in cervical cancer
    Chastan, Mathieu
    Manrique, Alain
    Baron, Marc
    Diologent, Brigitte
    Edet-Sanson, Agathe
    Guernou, Mohamed
    Modezelewski, Romain
    Vera, Pierre
    Hitzel, Anne
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [43] 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas
    Iagaru, Andrei
    Chawla, Sant
    Menendez, Lawrence
    Conti, Peter S.
    NUCLEAR MEDICINE COMMUNICATIONS, 2006, 27 (10) : 795 - 802
  • [44] Identification of Isolated Hepatic Sarcoidosis With 18F-FDG PET/CT and MRI
    Arnfield, Evyn
    Pattison, David A.
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : E448 - E450
  • [45] Value of 18F-FDG PET/CT in the Detection of Ovarian Malignancy
    Park T.
    Lee S.
    Park S.
    Lee E.
    Pahk K.
    Rhee S.
    Cho J.
    Kim C.
    Eo J.S.
    Choe J.G.
    Kim S.
    Nuclear Medicine and Molecular Imaging, 2015, 49 (1) : 42 - 51
  • [46] Detection of liver metastases in patients with adenocarcinomas of the gastrointestinal tract: comparison of 18F-FDG PET/CT and MR imaging
    Maegerlein, Christian
    Fingerle, Alexander A.
    Souvatzoglou, Michael
    Rummeny, Ernst J.
    Holzapfel, Konstantin
    ABDOMINAL IMAGING, 2015, 40 (05): : 1213 - 1222
  • [47] Detection of liver metastases in patients with adenocarcinomas of the gastrointestinal tract: comparison of 18F-FDG PET/CT and MR imaging
    Christian Maegerlein
    Alexander A. Fingerle
    Michael Souvatzoglou
    Ernst J. Rummeny
    Konstantin Holzapfel
    Abdominal Imaging, 2015, 40 : 1213 - 1222
  • [48] Comparison of [18 F] FDG PET/CT and [18 F]FDG PET/MRI in the Detection of Distant Metastases in Breast Cancer: A Meta-Analysis
    Shen, Fangqian
    Liu, Qi
    Wang, Yishuang
    Chen, Can
    Ma, Hu
    CLINICAL BREAST CANCER, 2025, 25 (02)
  • [49] Images of Sonazoid-enhanced ultrasonography in multistep hepatocarcinogenesis: comparison with Gd-EOB-DTPA-enhanced MRI
    Hideko Ohama
    Yasuharu Imai
    Osamu Nakashima
    Sachiyo Kogita
    Manabu Takamura
    Masatoshi Hori
    Yasushi Seki
    Yoshiyuki Sawai
    Takumi Igura
    Kazuto Fukuda
    Yuki Makino
    Osakuni Morimoto
    Masahiko Ohsawa
    Michiie Sakamoto
    Takamichi Murakami
    Journal of Gastroenterology, 2014, 49 : 1081 - 1093
  • [50] Diagnostic value of 18F-FDG PET/CT for atypical hepatic hemangioma
    Wang, Jianlin
    Shi, Aiqi
    Ding, Xiaofang
    Liu, Jiangyan
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (01) : 98 - 100